+39 02 610346.1 - info@newron.com

Our approach

Our approach

Newron is committed to developing novel therapies for patients with diseases of the central and peripheral nervous system. We are looking to build our portfolio of products through in-house efforts as well as licensing and acquiring novel CNS compounds at various stages of development. 

Newron has proven expertise in developing novel CNS and orphan products having taken a number of programs through pre-clinical, clinical phases and to market. Safinamide, our lead product, is commercialised by Newron’s partner Zambon and has received marketing authorization for the treatment of Parkinson’s Disease in a number of European countries, Switzerland and the U.S.

We are seeking partners who can complement our in-house CNS development capabilities and who share our ambition to deliver effective treatments to patients living with debilitating neurodegenerative  and or rare diseases. We have a promising pipeline of novel therapies and are looking to enter licensing or co-development agreements that will enable us to realize their full potential.